Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study Authors: Yuanyuan Zhao, Hongyun Zhao, Qiming Wang, Kunyu Yang, Yongsheng Li, Zhenming Fu, Weihua Yang, Zhiyong He, Yongsheng Wang, Yuxiang Ma, Yunpeng Yang, Wenfeng Fang, Sa Xiao, Hai Zhu, Yi Zhu, Li Zhang, Yan Huang Published: 2026 ABSTRACT PURPOSESmall cell lung cancer (SCLC) remains one of the most aggressive malignancies, with limited treatment options beyond frontline chemo-immunotherapy. Izalontamab brengitecan (iza-bren, BL-B01D1) is a first-in-class bispecific antibody-drug conjugate cotargeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3). We expanded the SCLC cohort to further evaluate the efficacy and safety of iza-bren in patients with extensive-stage SCLC (ES-SCLC).METHODSThis open-label, multicenter, dose-expansion phase Ib study (ClinicalTrials.gov identifier: NCT05194982) enrolled patients with ES-SCLC who had progressed on prior systemic therapies. Patients received iza-bren 2.5 mg/kg once daily on days 1 and 8 of each 3-week cycle. The primary end points were objective response rate (ORR) and safety/tolerability. Secondary end points included disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Exploratory end point included the assessment of potential associations between EGFR/HER3 expression and clinical outcomes.RESULTSAs of December 5, 2024, 52 patients were enrolled. The ORR was 48.1% (95% CI, 34.0 to 62.4), with a median PFS of 4.1 months (95% CI, 3.0 to 5.5) and a median OS of 12.2 months (95% CI, 9.1 to 13.2). In patients who received iza-bren as second-line treatment (n = 22), the ORR was 72.7% (95% CI, 49.8 to 89.3), median PFS 6.2 months (95% CI, 3.7 to 8.2), and median OS 15.0 months (95% CI, 8.7 to not reached). The most common treatment-related adverse events were hematologic toxicities (neutropenia, thrombocytopenia, anemia, and leukopenia). Exploratory biomarker analysis suggested that positive HER3 expression may be associated with better treatment response.CONCLUSIONIza-bren showed encouraging antitumor activity in relapsed ES-SCLC, particularly in the second-line setting. A phase III randomized controlled trial of iza-bren compared with topotecan (ClinicalTrials.gov identifier: NCT06500026) is ongoing. INTRODUCTION Small cell lung cancer (SCLC) remains one of the most aggressive and lethal malignancies, with limited treatment options beyond frontline chemo-immunotherapy.1,2 Despite initial response, the vast majority of patients relapse within months, with median overall survival (OS) rarely exceeding 12 months.3,4 Antibody-drug conjugates (ADCs) have emerged as a promising class of therapies by selectively delivering cytotoxic payloads to tumor cells, yet most efforts in SCLC have centered on lineage-specific targets such as DLL3 or CD276.5-9 Although epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3) are not classical therapeutic targets in SCLC, EGFR protein expression is observed in a substantial subset of patients, with historical reported rates ranging from 33% to 37%,10-13 and HER3 contributes to cell survival through heterodimerization with other ErbB receptors, including EGFR.14 Preclinical studies have implicated HER3 in lineage plasticity, drug tolerance, and resistance to chemotherapy and immunotherapy.15 These findings provide a biologic rationale for dual targeting of EGFR and HER3 to overcome intratumoral heterogeneity and adaptive resistance in relapsed SCLC. CONTEXT Key Objective To evaluate the efficacy and safety of izalontamab brengitecan (iza-bren), a first-in-class bispecific antibody-drug conjugate targeting EGFR and HER3, in patients with extensive-stage small cell lung cancer (ES-SCLC). Knowledge Generated In this phase Ib study, iza-bren demonstrated robust antitumor activity in relapsed ES-SCLC, achieving an objective response rate (ORR) of 48.1% (95% CI, 34.0 to 62.4), a median progression-free survival of 4.1 months, and a median overall survival of 12.2 months. Notably, iza-bren showed particularly high efficacy in the second-line setting, with an ORR of 72.7%. Exploratory biomarker analysis suggested a potential association between HER3 expression and clinical response. Relevance (T.E. Stinchcombe) Additional trials of izalontamab brengitecan in SCLC are warranted based on the preliminary efficacy and safety data.**Relevance section written by JCO Associate Editor Thomas E. Stinchcombe, MD. Key Objective Key Objective To evaluate the efficacy and safety of izalontamab brengitecan (iza-bren), a first-in-class bispecific antibody-drug conjugate targeting EGFR and HER3, in patients with extensive-stage small cell lung cancer (ES-SCLC). To evaluate the efficacy and safety of izalontamab brengitecan (iza-bren), a first-in-class bispecific antibody-drug conjugate targeting EGFR and HER3, in patients with extensive-stage small cell lung cancer (ES-SCLC). Knowledge Generated Knowledge Generated In this phase Ib study, iza-bren demonstrated robust antitumor activity in relapsed ES-SCLC, achieving an objective response rate (ORR) of 48.1% (95% CI, 34.0 to 62.4), a median progression-free survival of 4.1 months, and a median overall survival of 12.2 months. Notably, iza-bren showed particularly high efficacy in the second-line setting, with an ORR of 72.7%. Exploratory biomarker analysis suggested a potential association between HER3 expression and clinical response. In this phase Ib study, iza-bren demonstrated robust antitumor activity in relapsed ES-SCLC, achieving an objective response rate (ORR) of 48.1% (95% CI, 34.0 to 62.4), a median progression-free survival of 4.1 months, and a median overall survival of 12.2 months. Notably, iza-bren showed particularly high efficacy in the second-line setting, with an ORR of 72.7%. Exploratory biomarker analysis suggested a potential association between HER3 expression and clinical response. Relevance (T.E. Stinchcombe) Relevance (T.E. Stinchcombe) Additional trials of izalontamab brengitecan in SCLC are warranted based on the preliminary efficacy and safety data.* Additional trials of izalontamab brengitecan in SCLC are warranted based on the preliminary efficacy and safety data.* *Relevance section written by JCO Associate Editor Thomas E. Stinchcombe, MD. *Relevance section written by JCO Associate Editor Thomas E. Stinchcombe, MD. Izalontamab brengitecan (iza-bren; BL-B01D1) is a first-in-class bispecific ADC designed to cotarget EGFR and HER3.16 The molecule consists of a bispecific IgG1 backbone conjugated to a topoisomerase I inhibitor payload (Ed-04) via a cleavable linker, with a high drug-to-antibody ratio (DAR) of 8.17 This structural design allows for simultaneous engagement of two ErbB receptors, facilitating internalization and intracellular payload release even in tumors with modest receptor density.17,18 In the previous phase I study, iza-bren demonstrated encouraging preliminary antitumor activity in patients with advanced solid tumors.16 In this phase Ib dose-expansion study, we report the clinical evaluation of iza-bren in patients with extensive-stage SCLC (ES-SCLC). The primary objectives were to assess safety, tolerability, and preliminary efficacy. Exploratory analyses included EGFR and HER3 expression profiles and their potential associations with treatment response. METHODS Study Design and Participants BL-B01D1-101 is an open-label, multicenter, dose-escalation and dose-expansion, phase I study (ClinicalTrials.gov identifier: NCT05194982).16 The SCLC cohort was specifically expanded during the phase Ib stage to enroll additional patients, as illustrated in the study design (Appendix Fig A1, online only). The study was approved by the institutional review board at each participating site and conducted in compliance with the Declaration of Helsinki and Good Clinical Practice guidelines. All patients provided written consent. Eligible patients had histologically or cytologically confirmed SCLC at the time of initial diagnosis, disease progression after at least one prior platinum-based chemotherapy, and a PD-(L)1 inhibitor. The most recent disease progression was confirmed by investigators using computed tomography (CT) or magnetic resonance imaging (MRI) scans. Patients were 18 years of age or older, with a life expectancy of at least 3 months, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and had adequate organ function; they had at least one measurable lesion based on the RECIST, version 1.1. Toxicity from previous antitumor therapy must have been alleviated to grade 1 or below, as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Laboratory tests during screening included hematology, blood chemistry, cardiac function, coagulation, infectious disease tests, and endocrine function. Patients with active brain metastases, uncontrolled comorbidities, or ECOG performance status >1 were excluded. The full inclusion and exclusion criteria and criteria for withdrawal from treatment are listed in the protocol (Protocols, online only). Drug and Administration The study drug (iza-bren) was supplied by the sponsor (Sichuan Baili Pharmaceutical, Chengdu, China). Iza-bren 2.5 mg/kg once daily on days 1 and 8 of each 3-week cycle was proposed as the recommended phase 2 dose based on safety, pharmacokinetics, and preliminary efficacy across solid tumor types. The drug was administered intravenously; the first infusion duration was 120 minutes, and subsequent infusions were 60-120 minutes (Protocols). Study Procedures Tumor response and progression were regularly assessed according to RECIST v1.1 per Response Evaluation Criteria. Partial response (PR) required a 30% decrease in the sum of diameters of target lesions from baseline, and progressive disease required a ≥20% increase in the sum of diameters from nadir with an absolute increase of at least 5 mm or the appearance of new lesions. Radiographic imaging (enhanced CT or MRI) was performed every 6 weeks (±7 days) during the first year of treatment and every 12 weeks (±7 days) thereafter. Brain imaging was mandatory for all patients to evaluate CNS metastases at baseline. During the treatment period, follow-up brain imaging was performed every 6 weeks for patients with baseline CNS involvement. For patients without CNS involvement at baseline, brain imaging was repeated if they subsequently developed symptoms related to brain metastasis. Survival was monitored continuously while patients were on treatment and every 3 months after treatment discontinuation. Safety was evaluated throughout the study until 28 days after the last dose or initiation of other antitumor treatment, and adverse events were graded according to the NCI's CTCAE, version 5.0. All serious adverse events or suspected unexpected serious adverse reactions were reported until 90 days after the last dose or initiation of other antitumor treatment. Additional details regarding these procedures are provided in the study protocol (Protocols). End Points Primary end points were objective response rate (ORR), defined as the proportion of patients with a complete or PR per RECIST version 1.1, and safety/tolerability. Secondary end points included duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), and OS. Exploratory end points included the associations between EGFR/HER3 expression and clinical outcomes. Statistical Analysis Safety was assessed in safety analysis population, which included all the patients who received at least one dose of iza-bren and had at least one safety assessment. Safety was summarized descriptively. Efficacy was assessed in an intention-to-treat (ITT) population that includes all patients who received at least one dose of iza-bren. Patients without any postbaseline tumor assessment were classified as not evaluable and were counted as nonresponders for ORR and DCR. Point estimate (eg, ORR, DCR) and the corresponding two-sided 95% exact binomial confidence intervals (Clopper-Pearson) are presented. The Kaplan-Meier methods were used to estimate medians for time-to-event end points (DOR, PFS and OS), with 95% CIs constructed using Brookmeyer-Crowley methods for median and Greenwood's formula for landmark rates. For PFS and DOR, patients without an event were censored at the date of their last adequate tumor assessment. For OS, patients were censored at the date they were last known to be alive. No formal hypothesis testing was planned for this expansion cohort. The sample size was chosen to provide a preliminary estimate of ORR with reasonable precision and to further characterize the safety profile. All statistical analyses were performed using SAS version 9.4 or above, R version 4.1.2, and Phoenix version 8.3 or above. The study was registered with ClinicalTrials.gov, NCT05194982. Biomarker Analyses EGFR and HER3 expression were evaluated in formalin-fixed, paraffin-embedded tissue from the pretreatment tumor samples collected per protocol (archived or fresh tissue within 2 years) using immunohistochemistry (IHC) at the central laboratory. EGFR/HER3 IHC staining used antibodies targeting EGFR (D38B1) and HER3 (D22C5). The definition of positive staining of EGFR and HER3 is provided in Appendix 1. Moreover, we reported in vitro assays assessing EGFR and HER3 surface levels and their association with iza-bren internalization and efficacy. Additional methodology information is included in Appendix 1. RESULTS Patients As of the data cutoff date on December 5, 2024 of this study, 52 patients received 2.5 mg/kg iza-bren once daily on days 1 and 8 of each 3-week cycle (Fig 1; Appendix Fig A1). Seven patients were continuing treatment. Forty-five patients discontinued treatment: 35 because of disease progression, seven because of intolerance, one because of treatment delay>28 days, and two for other reasons (Fig 1). Flow diagram. Q3W, once every 3 weeks; SCLC, small cell lung cancer. Baseline clinical characteristics are shown in Table 1. Most patients were male (80.8%), with a median age of 60.5 years. Seventeen patients (32.6%) had brain metastasis at screening. Thirty patients (57.7%) received at least two prior lines of therapy. TABLE 1.Baseline CharacteristicsCharacteristic2.5 mg/kg Once Daily on D1 and D8 Q3W (N = 52)Age, years, median (Q1, Q3)60.5 (56.0, 65.0)Sex, No. (%) Male42 (80.8) Female10 (19.2)Smoking history, No. (%) Current or ever40 (76.9) Never12 (23.1)ECOG performance status, No. (%) 01 (1.9) 151 (98.1)Baseline SOD, mm, median (range)60.6 (11.0-195.0)Metastasis organs, No., median (range)2 (0-7)Metastasis at screening, No. (%)17 (32.6)Prior lines of therapy, No. (%) 1L22 (42.3) 2L11 (21.2) 3L and above19 (36.5)Prior lines of chemotherapy, No. (%) 1L23 (44.2) 2L19 (36.5) 3L and above10 (19.2)Previous platinum-based chemotherapy, No. (%)52 (100.0)Previous anti–PD-1/L1 immunotherapy, No. (%)44 (84.6)Previous treatment of irinotecan, No. (%)19 (36.5)Abbreviations: ECOG, Eastern Cooperative Oncology Group; n, number; Q, quartile; Q3W, once every 3 weeks; SOD, sum of diameter. Baseline Characteristics Abbreviations: ECOG, Eastern Cooperative Oncology Group; n, number; Q, quartile; Q3W, once every 3 weeks; SOD, sum of diameter. Efficacy In the SCLC cohort receiving 2.5 mg/kg iza-bren once daily on days 1 and 8 of every 3 weeks (n = 52, ITT), 25 patients achieved a PR (ORR, 48.1% [95% CI 34.0 to 62.4]) and 17 achieved stable disease, for a DCR of 80.8% (95% CI, 67.5 to 90.4; Table 2; Fig 2A; Appendix Fig A2). Six patients had no postbaseline tumor assessment and were classified as not evaluable; they were counted as nonresponders in ITT analyses (Table 2). Among the 25 responders, 18 events (72.0%, 18/25) were documented, with a median DOR of 4.9 months (95% CI, 4.2 to 6.7). Regarding survival outcomes, 45 PFS events (86.5%) and 31 OS events (59.6%) occurred by the data cutoff. The median PFS was 4.1 months (95% CI, 3.0 to 5.5; Fig 2B), and the median OS was 12.2 months (95% CI, 9.1 to 13.2; Fig 2C). TABLE 2.Antitumor ActivityVariableTotal (N = 52)Only 1 Prior Linea (n = 22)2 and Above Prior Lines (n = 30)Line of treatment, median (range)2 (1-7)1 (1-1)3 (2-7)BOR, No. PR25169 SD17413 PD413 NE615ORR, % (95% CI)48.1 (34.0 to 62.4)72.7 (49.8 to 89.3)30.0 (14.7 to 49.4)DCR, % (95% CI)80.8 (67.5 to 90.4)90.9 (70.8 to 98.9)73.3 (54.1 to 87.7)DOR, months, median (95% CI)4.9 (4.2 to 6.7)4.9 (3.1 to 6.7)4.4 (3.0 to 7.0)PFS, months, median (95% CI)4.1 (3.0 to 5.5)6.2 (3.7 to 8.2)3.0 (2.6 to 4.4)OS, months, median (95% CI)12.2 (9.1 to 13.2)15.0 (8.7 to NR)10.3 (7.9 to 12.4)Abbreviations: BOR, best overall response; DCR, disease control rate; DOR, duration of response; NE, not evaluable; NR, not reached; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease. a All 22 patients in this subgroup received one prior line of platinum-based chemotherapy, of whom 20 also received a PD-(L)1 inhibitor as part of that line. Antitumor Activity Abbreviations: BOR, best overall response; DCR, disease control rate; DOR, duration of response; NE, not evaluable; NR, not reached; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease. All 22 patients in this subgroup received one prior line of platinum-based chemotherapy, of whom 20 also received a PD-(L)1 inhibitor as part of that line. Antitumor efficacy of iza-bren 2.5 mg/kg once daily on days 1 and 8 of each 3-week cycle in advanced ES-SCLC. (A-C) Efficacy in the overall SCLC cohort (N = 52). (A) Waterfall plot of the best percentage change from baseline in the sum of target lesions. (B) Kaplan-Meier estimates of PFS. (C) Kaplan-Meier estimates of OS. (D-F) Efficacy in the subgroup of patients who had only one prior line therapy and received iza-bren as second-line treatment (n = 22). (D) Waterfall plot of the best percentage change from baseline in the sum of target lesions. (E) Kaplan-Meier estimates of PFS. (F) Kaplan-Meier estimates of OS. NR, not reached; PBC, platinum-based chemotherapy; PFS, progression-free survival; OS, overall survival; SCLC, small cell lung cancer. Among the 22 (42.3%) patients who had only one prior line therapy and received iza-bren as second-line treatment, the ORR was 72.7% (95% CI, 49.8 to 89.3), and the DCR was 90.9% (95% CI, 70.8 to 98.9; Table 2; Fig 2D). The median DOR was 4.9 months (95% CI, 3.1 to 6.7), the median PFS was 6.2 months (95% CI, 3.7 to 8.2; Fig 2E), and the median OS was 15.0 months (95% CI, 8.7 to not reached; Fig 2F). The platinum-sensitive subgroup (defined as a treatment-free interval of >6 months following front-line platinum-based therapy; n = 13), demonstrated an ORR of 69.2% (95% CI, 38.6 to 90.9) and a DCR of 84.6% (95% CI, 54.6 to 98.1; Appendix Table A1). Among 19 (36.5%) patients previously treated with irinotecan, iza-bren demonstrated an ORR of 31.6% (95% CI, 12.6 to 56.6) and a DCR of 68.4% (95% CI, 43.4 to 87.4; Appendix Table A2). Safety Safety findings are summarized in the Table 3. The most common treatment-related adverse events (TRAEs) were hematologic and gastrointestinal in nature, including anemia, neutropenia, thrombocytopenia, and stomatitis. Grade 3 or higher TRAEs occurred in 75% of patients, leading to dose reductions in 46% and treatment discontinuation in 13%. TABLE 3.Treatment-Related Adverse Events (safety population)Event2.5 mg/kg Once Daily on D1 and D8 Q3W (N = 52), No. (%)All GradeGrade 1 to 2Grade 3Grade 4Grade 5Any TRAE52 (100.0)13 (25.0)20 (38.5)15 (28.8)4 (7.7)Treatment-related SAEs26 (50.0)TRAEs leading to death2 (3.8)TRAEs leading to discontinuation of study drug7 (13.5)TRAEs leading to dose reduction24 (46.2)TRAEs leading to drug delay33 (63.5)TRAEs in ≥15% of all patients or TRAEs grade ≥ 3 Anemia44 (84.6)26 (50.0)17 (32.7)1 (1.9)0 Leukopenia38 (73.1)23 (44.2)12 (23.1)3 (5.8)0 Thrombocytopenia39 (75.0)18 (34.6)11 (21.2)10 (19.2)0 Neutropenia37 (71.2)14 (26.9)15 (28.8)8 (15.4)0 Asthenia22 (42.3)21 (40.4)1 (1.9)00 Hypoalbuminemia22 (42.3)22 (42.3)000 Stomatitis19 (36.5)14 (26.9)5 (9.6)00 Hyponatremia18 (34.6)16 (30.8)1 (1.9)1 (1.9)0 Nausea16 (30.8)15 (28.8)1 (1.9)00 Vomiting14 (26.9)13 (25.0)1 (1.9)00 Diarrhea14 (26.9)13 (25.0)1 (1.9)00 Hypokalemia16 (30.8)15 (28.8)1 (1.9)00 Decreased appetite10 (19.2)10 (19.2)000 Alanine aminotransferase increased12 (23.1)11 (21.2)1 (1.9)00 Dizziness9 (17.3)9 (17.3)000 Weight decreased10 (19.2)10 (19.2)000 Myelosuppression8 (15.4)02 (3.8)6 (11.5)0 Constipation8 (15.4)8 (15.4)000 Hypophagia8 (15.4)8 (15.4)000 Lymphocyte count decreased8 (15.4)4 (7.7)2 (3.8)2 (3.8)0 Hypoesthesia6 (11.5)5 (9.6)1 (1.9)00 Febrile neutropenia2 (3.8)01 (1.9)1 (1.9)0 Death2 (3.8)0002 (3.8) Gastrointestinal infection2 (3.8)01 (1.9)01 (1.9) Acute kidney injury1 (1.9)001 (1.9)0 Cardiac failure1 (1.9)01 (1.9)00 Coagulopathy1 (1.9)01 (1.9)00 Gastrointestinal hemorrhage1 (1.9)001 (1.9)0 Intestinal obstruction1 (1.9)01 (1.9)00 Oral disorder1 (1.9)01 (1.9)00 Renal impairment1 (1.9)01 (1.9)00 Respiratory failure1 (1.9)0001 (1.9)Abbreviations: SAE, serious adverse event; TRAE, treatment-related adverse event; Q3W, once every 3 weeks. Treatment-Related Adverse Events (safety population) Abbreviations: SAE, serious adverse event; TRAE, treatment-related adverse event; Q3W, once every 3 weeks. No treatment-related interstitial lung disease was observed. Two patients (3.8%) experienced grade 5 TRAEs leading to death (one case of respiratory failure and one gastrointestinal infection). Two sudden deaths of unknown cause were considered not related to study drug by investigators. Biomarker Analysis Biomarker analyses were exploratory and limited by sample size. Tumor tissue specimens were available from 26 patients; IHC assays for EGFR and HER3 were conducted in these patients. Baseline characteristics are demonstrated in Appendix Table A3. Eleven (42.3%) patients showed positive EGFR expression, whereas 15 (57.7%) patients were negative. Positive HER3 expression was found in 17 (65.4%) patients while negative in nine (34.6%) patients. Among 23 patients who were evaluable for response within the biomarker subset, 10 (43.5%) patients showed positive EGFR expression and 16 (69.6%) patients showed positive HER3 expression. The ORR of the 23 patients was 52.2%. The ORR of patients with positive and negative EGFR was comparable: EGFR positive 50.0% (5/10) versus EGFR negative 53.8% (7/13; Fig 3A). However, patients with positive HER3 expression demonstrated higher ORR (68.8% [11/16]) than those with negative HER3 expression (14.3% [1/7]; Fig 3A). Thus, within this small exploratory biomarker subset, EGFR expression was not associated with clinical response, whereas HER3 positivity appeared to enrich for response. Exploratory in vitro analyses of EGFR/HER3 expression, iza-bren internalization, and cytotoxic sensitivity in SCLC cell lines. (A) Bar plot illustrating the ORR in patients stratified by EGFR expression (positive v negative) and HER3 expression (positive v negative). Red bars represent positive expression status, and blue bars represent negative expression status. Cell surface expression levels of EGFR (B) and HER3 (C) across different SCLC cell lines as determined by flow cytometry. (D) SCLC cells lines were incubated with iza-bren-TAB conjugated to a red fluorescent pH-sensitive dye (pHrodo-(iza-bren)-TAB). Intracellular red fluorescent signals correspond to iza-bren-TAB reaching the endo-lysosomal compartments (top). Quantification of experiments showing normalized pHrodo intensity per cell over time. Data are presented as mean ± SEM at the indicated time point (n = 3 biologic replicates per group) (bottom). (E) Fitted dose-response curves of SCLC cells exposed to iza-bren in vitro. IC50, half maximal inhibitory concentration; EGFR, epidermal growth factor receptor; HER3, human epidermal growth factor receptor 3; ORR, objective response rate; RCU, red calibrated unit; SCLC, small cell lung cancer. In vitro analyses, we evaluated the cell surface expression of EGFR and HER3 across a panel of SCLC cell lines using flow cytometry (Figs 3B and 3C). Subsequent assays showed that iza-bren internalization tended to be greater in cell lines with higher EGFR expression, including NCI-H1048, NCI-H2286, and NCI-H1339 (Fig 3D). However, NCI-H1339 showed efficient internalization but relatively poor cytotoxic sensitivity, indicating that EGFR-associated internalization alone is not sufficient to determine iza-bren activity (Fig 3E). Cytotoxic sensitivity appeared more closely aligned with HER3 abundance in this limited cell-line panel (such as NCI-H1048, DMS114, and NCI-H2286) as reflected by lower IC50 values (Fig 3E). Downstream determinants such as payload sensitivity, intracellular trafficking, and DNA damage response, which may influence iza-bren activity, were not characterized in this study. DISCUSSION In this phase Ib study, iza-bren demonstrated encouraging antitumor activity in patients with ES-SCLC. The ORR was 48.1%, with a median PFS of 4.1 months and a median OS of 12.2 months. Notably, patients receiving iza-bren as second-line therapy achieved an ORR of 72.7%, and a median OS of 15.0 months, numerically superior to the current second-line treatments.19,20 For patients with progression after second-line topoisomerase I inhibitor (eg, topotecan, irinotecan), subsequent systemic options typically yield limited response rate.21-23 In this study, among patients previously treated with irinotecan, iza-bren also demonstrated an ORR of 31.6% and a median DOR of 5.7 months. The predominant TRAEs were hematologic toxicities, which were manageable with supportive measures and dose modifications. No interstitial lung disease was recorded as of the data cutoff, suggesting a low risk of pulmonary toxicity in this cohort, although continued monitoring is warranted. Predictive biomarkers for ADCs in SCLC remain elusive and complex.24,25 In this study, HER3 expression appeared to be associated with response. However, these findings should be interpreted with caution given this small, hypothesis-generating subset, and heterogeneous tissue timing. A more nuanced understanding of EGFR/HER3 abundance and functional receptor engagement in SCLC will require larger, prospectively collected data sets. Moreover, in vitro analyses in our study demonstrated that HER3 expression was associated with iza-bren sensitivity, whereas EGFR levels aligned with internalization but may not be sufficient for cytotoxic activity. Consequently, additional study is needed to precisely characterize the intrinsic sensitivity of various SCLC cell lines to the topoisomerase I inhibitor payload. Furthermore, more extensive cytologic investigations involving receptor perturbation techniques (such as siRNA or CRISPR/Cas9) are warranted to delineate the specific roles of EGFR and HER3 in the internalization process. In parallel, dedicated experiments using mono-specific parental antibodies targeting EGFR or HER3 individually will be required to evaluate their respective contributions to intracellular drug release and overall antitumor activity. Although iza-bren was designed to engage both EGFR and HER3, the present clinical biomarker data do not demonstrate that EGFR expression contributes independently to response, and the mechanistic role of EGFR in iza-bren activity remains uncertain. The current findings should be interpreted primarily as clinical evidence of antitumor activity, with biomarker and in vitro results serving as hypothesis-generating observations. Further studies exploring the mechanism of bispecific synergy are needed. We acknowledge several limitations. The single-arm design and limited sample size, particularly for subgroup analysis, constrain definitive conclusions. Furthermore, our translational findings remain exploratory and hypothesis-generating. Thus, larger prospective cohorts and more extensive mechanistic studies are warranted to validate these preliminary observations and further elucidate the underlying biologic mechanisms. In summary, iza-bren demonstrated encouraging antitumor activity and a manageable safety profile in relapsed ES-SCLC. The ongoing phase III trial (ClinicalTrials.gov identifier: NCT06500026) will provide more definitive evidence.